autologous bone marrow mononuclear cells (UTHealth Houston, 4c7607)

Autologous bone marrow mononuclear cell (BMMNC) therapy is an investigational cell-based biologic developed for the treatment of cardiac injury following an acute myocardial infarction (AMI). Investigated by The University of Texas Health Science Center at Houston as part of the Cardiovascular Cell Therapy Research Network (CCTRN), the therapy involves the extraction of a patient's own bone marrow, followed by the isolation and intracoronary infusion of approximately 150 million mononuclear cells. The specific protocol evaluated in the LateTIME Phase II trial focused on administering these cells 2 to 3 weeks after the initial infarction in patients with significant left ventricular dysfunction (LVEF ≤ 45%). The therapeutic rationale is based on the potential for these cells to secrete paracrine factors that inhibit cardiomyocyte apoptosis, promote angiogenesis, and attenuate adverse ventricular remodeling. However, clinical results published in 2011 demonstrated that this specific intervention did not significantly improve left ventricular ejection fraction or reduce ventricular volumes compared to placebo.

Other names

BMMNCadult stem cellsautologous BMMNCsbone marrow mononuclear cells